Ultimately, our data identified a tumour suppressor role for G0S2 in CML survival and TKI resistance that was independent from its canonical function as an inhibitor of ATGL. This evidence concerns the gene G0S2 and chronic myelogenous leukemia, BCR-ABL1 positive.